149,626 Shares in Amgen Inc. $AMGN Bought by Nykredit A S

Nykredit A S purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 149,626 shares of the medical research company’s stock, valued at approximately $54,183,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Adell Harriman & Carpenter Inc. increased its holdings in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen during the 4th quarter worth $22,441,000. National Pension Service increased its position in shares of Amgen by 4.7% in the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock worth $405,717,000 after purchasing an additional 55,489 shares during the period. Integrated Advisors Network LLC raised its position in shares of Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after buying an additional 6,356 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Amgen by 2.5% during the fourth quarter. Legal & General Group Plc now owns 3,811,451 shares of the medical research company’s stock valued at $1,247,526,000 after purchasing an additional 94,494 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AMGN shares. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Robert W. Baird raised their price target on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group lifted their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Daiwa Securities Group dropped their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Piper Sandler increased their price target on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $380.43.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $442.84 on Thursday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $447.03. The firm has a market capitalization of $239.41 billion, a price-to-earnings ratio of 27.52, a PEG ratio of 3.16 and a beta of 0.43. The stock’s 50 day moving average is $393.99 and its 200-day moving average is $366.13. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New evidence that Amgen’s cholesterol drug Repatha reduced the risk of death among patients at high risk of heart attack or stroke strengthens the drug’s clinical profile and could support broader use, sales growth and reimbursement. Amgen’s Repatha reduces risk of death in people at high risk of heart attack or stroke
• Positive Sentiment: Commentary highlighted Repatha’s potentially significant cardiovascular opportunity, adding to investor enthusiasm about a product that could become an important long-term growth driver beyond Amgen’s current results. Jim Cramer on Amgen’s cardiovascular opportunity
• Positive Sentiment: Analyst H. Engel of Erste Group raised the firm’s 2027 EPS estimate to $24.43 from $23.50, signaling improved expectations for Amgen’s earnings trajectory, although the firm maintained a Hold rating.
• Neutral Sentiment: Amgen will present at the Wells Fargo Healthcare Conference, giving investors a potential update on its pipeline, commercial outlook and strategy. The announcement itself contains no new financial guidance. Amgen to present at the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: U.K. regulators suspended Tavneos for new patients and halted its sale after determining that the main supporting study contained unreliable data. The action threatens sales of the rare-disease treatment and raises the risk of additional regulatory scrutiny or restrictions in other markets. UK regulator suspends Amgen’s Tavneos for new patients

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.